(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 July 2020 (30.07.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/152308 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 9/12* (2006.01)
A61P 9/10 (2006.01)

(21) International Application Number:
PCT/EP2020/051707

(22) International Filing Date:
24 January 2020 (24.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2019/051874
25 January 2019 (25.01.2019) EP
PCT/EP2019/060152
18 April 2019 (18.04.2019) EP
PCT/EP2019/066495
21 June 2019 (21.06.2019) EP
PCT/EP2019/067187
27 June 2019 (27.06.2019) EP


(71) Applicant: **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH).

(72) Inventors: **CSONKA, Dénes**; c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16, 4123 Allschwil (CH). **FARES, Wassim**; c/o Janssen Research & Development LLC 1820 Chapel Avenue West, Suite #300, Cherry Hill, NJ 08002 (US). **HOOGKAMER, Hans**; c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16, 4123 Allschwil (CH). **TORFS, Koen**; c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **RUHLMANN, Eric**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil (CH).

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Figure 1



(57) Abstract: The present invention relates to high doses of macitentan (INN), i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, the present invention relates to the use of high doses of macitentan or of aprocitentan for the manufacture of a medicament for the treatment and/or prevention of CTEPH, as well as to a method for the treatment and/or prevention of CTEPH comprising administering high doses of macitentan or of aprocitentan to a patient. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of CTEPH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Moreover, the present invention relates to a pharmaceutical composition for the treatment of CTEPH comprising a high dose of macitentan or of aprocitentan.

WO 2020/152308 A1

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*